What is the ROCE (Return on Capital Employed) of ImmunoGen this year?
The ROCE of ImmunoGen is -1.42 undefined this year.
ImmunoGen ROCE 2025
ImmunoGen ROCE
-1.42
Ticker
IMGN
ISIN
US45253H1014
WKN
878613
In 2025, ImmunoGen's return on capital employed (ROCE) was -1.42, a 0% increase from the 0 ROCE in the previous year.
ImmunoGen Aktienanalyse
What does ImmunoGen do?
ImmunoGen Inc is a leading company in the biotechnology industry. The company was founded in 1981 as a research facility. In recent decades, ImmunoGen Inc has specialized in the development of antibody-drug conjugates (ADCs). ADCs are drugs that consist of an antibody and a cytotoxin that specifically targets tumor cells. In this way, cancer cells can be selectively destroyed without damaging surrounding tissue. ImmunoGen Inc has achieved success in recent years, particularly in the development of ADCs against serious cancers such as lung cancer or breast cancer, and it also collaborates with major pharmaceutical companies such as Roche or Bayer. The business model of ImmunoGen Inc, therefore, consists of developing innovative cancer drugs and successfully bringing them to market. Another branch of the company is the development of therapeutics for other diseases such as rheumatoid arthritis or multiple sclerosis. ImmunoGen Inc also utilizes ADCs to selectively destroy disease-specific cells in these cases. In the past, ImmunoGen Inc has successfully launched several products on the market. For example, in 2019, the cancer drug Kadcyla, manufactured by Roche and based on ImmunoGen's ADC technology, was approved by the US Food and Drug Administration (FDA) for the treatment of certain types of breast cancer. The ADC development candidate IMGN632 also shows promising results in the treatment of acute myeloid leukemia and other cancer diseases. The history of ImmunoGen Inc has also been marked by some challenges. In the early years of the company, it faced financial difficulties and sold a large number of shares to an investor in 1999. However, the company remained diligent in research and development and eventually became one of the leading biotech companies in the field of cancer research with the development of ADCs. Nevertheless, the company has also experienced setbacks in the development of products and has had to discontinue several development programs. Despite everything, ImmunoGen Inc is considered a successful company in the biotechnology industry, effectively marketing its innovative solutions in the oncology market. It is also being closely watched to see whether future ADCs will not have to undergo as long development cycles as their predecessors, which can guarantee long-term success for the company. ImmunoGen ist eines der beliebtesten Unternehmen auf Eulerpool.com.ROCE Details
Unraveling ImmunoGen's Return on Capital Employed (ROCE)
ImmunoGen's Return on Capital Employed (ROCE) is a financial metric that measures the company's profitability and efficiency with respect to the capital employed. It is calculated by dividing earnings before interest and tax (EBIT) by the employed capital. A higher ROCE indicates that the company is effectively utilizing its capital to generate profits.
Year-to-Year Comparison
Analyzing ImmunoGen's ROCE annually provides valuable insights into its efficiency in using its capital to generate profits. An increasing ROCE indicates improved profitability and operational efficiency, whereas a decrease might signal potential issues in capital utilization or business operations.
Impact on Investments
ImmunoGen's ROCE is a critical factor for investors and analysts for evaluating the company’s efficiency and profitability. A higher ROCE can make the company an attractive investment, as it often signifies that the firm is generating adequate profits from its employed capital.
Interpreting ROCE Fluctuations
Changes in ImmunoGen’s ROCE are attributed to variations in EBIT or the capital employed. These fluctuations offer insights into the company’s operational efficiency, financial performance, and strategic financial management, assisting investors in making informed investment decisions.
Frequently Asked Questions about ImmunoGen stock
How has the ROCE (Return on Capital Employed) of ImmunoGen developed compared to the previous year?
The ROCE of ImmunoGen has increased by 0% decreased compared to the previous year.
What does a high ROCE (Return on Capital Employed) mean for investors of ImmunoGen?
A high Return on Capital Employed (ROCE) indicates that ImmunoGen has efficient capital utilization and is able to achieve a higher return on its invested capital. This can be appealing to investors.
What does a low ROCE (Return on Capital Employed) mean for investors of ImmunoGen?
A low ROCE (Return on Capital Employed) can indicate that ImmunoGen has an inefficient utilization of its capital and may have difficulty in achieving a satisfactory return on its invested capital. This can be uncertain or unattractive for investors.
How does an increase in ROCE from ImmunoGen impact the company?
An increase in the ROCE of ImmunoGen can be an indicator of improved company efficiency and show that it is achieving higher profits in relation to its investments.
How does a reduction in the ROCE of ImmunoGen affect the company?
A decrease in ROCE of ImmunoGen can be an indicator of deteriorated efficiency of the company, indicating that it is generating lower profits in relation to its investments.
What are some factors that can influence the ROCE of ImmunoGen?
Some factors that can affect ImmunoGen's ROCE include efficiency in managing assets, profitability of investments, cost efficiency, and market conditions.
Why is the ROCE of ImmunoGen so important for investors?
The ROCE of ImmunoGen is important for investors as it is an indicator of the company's efficiency and shows how successful the company is in relation to its investments. A high ROCE can indicate strong financial performance of the company.
What strategic measures can ImmunoGen take to improve the ROCE?
To improve the ROCE, ImmunoGen can take measures such as increasing efficiency in asset management, optimizing investments, cost savings, and exploring new revenue sources. It is important for the company to conduct a thorough review of its operations to determine the best strategic actions to improve the ROCE.
How much dividend does ImmunoGen pay?
Over the past 12 months, ImmunoGen paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, ImmunoGen is expected to pay a dividend of 0 USD.
What is the dividend yield of ImmunoGen?
The current dividend yield of ImmunoGen is .
When does ImmunoGen pay dividends?
ImmunoGen pays a quarterly dividend. This is distributed in the months of .
How secure is the dividend of ImmunoGen?
ImmunoGen paid dividends every year for the past 0 years.
What is the dividend of ImmunoGen?
For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.
In which sector is ImmunoGen located?
ImmunoGen is assigned to the 'Health' sector.
Wann musste ich die Aktien von ImmunoGen kaufen, um die vorherige Dividende zu erhalten?
To receive the latest dividend of ImmunoGen from 1/30/2025 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 1/30/2025.
When did ImmunoGen pay the last dividend?
The last dividend was paid out on 1/30/2025.
What was the dividend of ImmunoGen in the year 2024?
In the year 2024, ImmunoGen distributed 0 USD as dividends.
In which currency does ImmunoGen pay out the dividend?
The dividends of ImmunoGen are distributed in USD.
Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.
Andere Kennzahlen von ImmunoGen
Our stock analysis for ImmunoGen Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of ImmunoGen Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.
